Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

PMID:
23219286
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Analysis of differences between indication and prescription of gastroprotection in patients with risk factors treated with nonsteroidal anti-inflammatory agents: the GAP study].

Lanas A, Muñoz M, Caballero Correa M, Martínez Jiménez P; investigadores del estudio GAP.

Gastroenterol Hepatol. 2010 Feb;33(2):80-91. doi: 10.1016/j.gastrohep.2009.09.009. Epub 2009 Nov 22. Spanish.

PMID:
19931944
[PubMed - indexed for MEDLINE]
3.

[The blood ammonia electroencephalogram pattern in the evaluation of portosystemic encephalopathy].

Bataller Sifre R, López Gómez LJ, Abella Llácer A, Berto Navarro R, González Marrtínez M.

Rev Esp Enferm Apar Dig. 1972 Feb 1;36(3):293-304. Spanish. No abstract available.

PMID:
5058815
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk